Qingyang

Researchers are evaluating the effects of different inhaled oxygen concentrations on lung function in older patients undergoing laparoscopic gastrointestinal surgery under general anesthesia. This multicenter, prospective, randomized controlled study compares low oxygen concentration 40% and high oxygen concentration 80% during surgery in patients aged 65 and older. The study aims to understand how these oxygen levels impact lung function and postoperative recovery. Participants will be randomly assigned to one of two groups one receiving 80% oxygen and the other receiving 40% oxygen after anesthesia induction. Both groups will follow a lung-protective ventilation strategy with specific respiratory parameters. Manual lung recruitment maneuvers will be performed after intubation and before extubation. Blood samples for gas analysis will be collected within 48 hours after surgery to assess outcomes. During the study, participants will be closely monitored with respiratory assessments and blood gas analyses, focusing on the oxygenation index 48 hours post-surgery. Secondary measures include pulmonary complications within 7 days and mortality within 30 days. The study involves multiple centers and plans to enroll 1098 subjects. The total duration of participation includes the surgical procedure and follow-up assessments up to 30 days after surgery.

Researchers are evaluating the long-term treatment of liver fibrosis in patients with chronic viral hepatitis B. This Phase IIIb extension trial builds on a previous randomized, double-blind, placebo-controlled study that assessed hydronidone capsules. The aim is to assess how effective and safe hydronidone capsules are over an extended period in managing liver fibrosis progression and reducing clinical endpoint events related to liver disease. Participants receive either hydronidone capsules or placebo capsules three times daily, with each dose consisting of three capsules taken half an hour before meals. Both groups also receive entecavir antiviral therapy once daily, or an alternative antiviral if entecavir is unsuitable. The treatment period in this extension trial lasts for five years, continuing the original protocol from the prior Phase III study. Throughout the study, participants undergo regular assessments including clinical laboratory tests every six months, evaluation of liver enzymes ALT and AST, hepatitis B viral load measurement, and transient elastography to monitor liver stiffness. The researchers track the cumulative incidence of clinical endpoint events over five years to evaluate treatment outcomes. The study also allows some flexibility in the frequency of examinations to improve participant compliance while maintaining at least yearly evaluations.